TMCIHealthcare · Medical DevicesThe 5 Wall Street analysts covering Treace Medical Concepts, Inc. hold a median 12-month price target of $5 — +12.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Treace Medical Concepts, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (86): Analysts have, on balance, been raising their forecasts.
Volatility (11): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TMCI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +12.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Truist Securities | Maintains | Hold | $4.00 → $5.00 |
| 16 July 2026 | Truist Securities | Maintains | Hold | $2.00 → $4.00 |
| 16 July 2026 | Truist Securities | Maintains | Hold | — |
| 2 Mar 2026 | Lake Street | Maintains | Buy | — |
| 7 Jan 2026 | Stifel | Maintains | Hold | — |
| 18 Dec 2025 | Truist Securities | Maintains | Hold | — |
| 10 Nov 2025 | Truist Securities | Reiterates | Hold | — |
| 7 Nov 2025 | BTIG | Downgrade | Neutral | — |
| 7 Nov 2025 | JP Morgan | Downgrade | Underweight | — |
| 7 Nov 2025 | UBS | Maintains | Neutral | — |
| 15 Oct 2025 | Truist Securities | Maintains | Hold | — |
| 4 Sept 2025 | Truist Securities | Maintains | Hold | — |
| 8 Aug 2025 | Stifel | Maintains | Hold | — |
| 8 Aug 2025 | UBS | Maintains | Neutral | — |
| 9 May 2025 | UBS | Maintains | Neutral | — |
| 11 Apr 2025 | Truist Securities | Maintains | Hold | — |
| 13 Mar 2025 | Truist Securities | Maintains | Hold | — |
| 3 Mar 2025 | Truist Securities | Maintains | Hold | — |
| 31 Dec 2024 | Lake Street | Initiates | Buy | — |
| 18 Dec 2024 | Truist Securities | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TMCI appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Treace Medical Concepts, Inc. returned −30.2% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 60% of US stocks
Cheaper than 22% of US stocks
Cheaper than 83% of US stocks
Higher than 21% of US stocks
Higher than 32% of US stocks
Higher than 90% of US stocks
Higher than 19% of US stocks
Higher than 13% of US stocks
Higher than 17% of US stocks
Higher than 21% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Treace Medical Concepts, Inc. has a market value of $288.1M and an enterprise value of $315.5M.
Revenue in the twelve months to 30 June 2026: $205.3M. The latest quarter shrank 4.2% year on year.
Net income over the same four quarters: −$59.5M, a −29.0% net margin.
Diluted earnings per share, trailing twelve months: $−0.93.
Free cash flow in the twelve months to 30 June 2026: −$25.0M.
Trailing P/E: −4.7×; forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Treace Medical Concepts, Inc. employs 450 people — $456K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Treace Medical Concepts, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Treace Medical Concepts announced it will release its third-quarter 2026 financial results before trading begins on November 6, 2026. Management will host a conference call to discuss the results at 8:00 a.m. ET that day.
Why it matters — TMCI watchers may note the scheduled date and time for the company’s quarterly results and management discussion.
A law firm is encouraging Treace Medical Concepts, Inc. shareholders to contact them about potential breaches of fiduciary duties by company insiders. The firm states it would handle any matter on a contingent fee basis, with no out-of-pocket legal costs for shareholders.
Why it matters — The announcement signals a potential shareholder investigation or legal action against TMCI insiders, which TMCI watchers would monitor for possible governance or legal developments.
Treace Medical Concepts announced the presentation of results from three clinical studies at the American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle, Washington. The presentations include data from the milestone 5-year ALIGN3D Lapiplasty study demonstrating sustained, positive outcomes, as well as the MTA3D Adductoplasty and SPRINT SpeedPlate clinical studies.
Why it matters — The 5-year ALIGN3D data showing sustained positive outcomes supports the evidence base for the company's flagship Lapiplasty procedure, which is central to Treace's business.
Treace Medical Concepts highlighted new product innovations and clinical data across its expanding foot and ankle portfolio at the 2026 AOFAS Annual Meeting. The company said the new product offerings extend its bunion market leadership and accelerate penetration into new foot and ankle market adjacencies.
Why it matters — TMCI watchers would care because the company is showcasing expanded product offerings and clinical data that position it to extend its leadership and enter new market segments within the foot and ankle space.
Treace Medical Concepts, Inc. (TMCI) published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The report identifies the source and subject matter of the call but provides no figures or details from the discussion.
Why it matters — TMCI watchers would care because the earnings call transcript is a primary source of information on the company's recent quarterly performance and management commentary.
The 5 Wall Street analysts covering Treace Medical Concepts, Inc. have a median 12-month price target of $5, with estimates ranging from $4.5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Treace Medical Concepts, Inc., 1 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Treace Medical Concepts, Inc. 54 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Treace Medical Concepts, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (86 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +12.9% from the last close, and Ticker Nerd's factor model ranks Treace Medical Concepts, Inc. 54 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Treace Medical Concepts, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMCI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.5 to $7 over the next 12 months.
Treace Medical Concepts, Inc. returned -30.2% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Treace Medical Concepts Inc. is a medical technology company focused on orthopedic solutions for foot and ankle care.
The most recent item we track (GlobeNewsWire, 23 Oct 2026): "Treace to Report Third Quarter 2026 Financial Results on November 6, 2026". Treace Medical Concepts announced it will release its third-quarter 2026 financial results before trading begins on November 6, 2026. Management will host a conference call to discuss the results at 8:00 a.m. ET that day.
Treace Medical Concepts Inc. is a medical technology company focused on orthopedic solutions for foot and ankle care. Its core offerings include surgical systems, instruments, implants, and biologic solutions designed for the treatment of bunion deformities and related midfoot conditions. The company’s product portfolio is centered on procedures that help surgeons address the underlying structure of hallux valgus, with systems such as Lapiplasty supporting three-dimensional bunion correction. Treace Medical Concepts serves orthopedic surgeons, podiatrists, ambulatory surgery centers, and other healthcare providers involved in foot and ankle surgery. Its products are used in commercial-stage clinical settings and are part of the broader medical devices market, where the company contributes specialized tools intended to improve procedural consistency and surgical workflow. Headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts operates as a focused player in the musculoskeletal device segment, with an emphasis on dedicated treatment solutions for bunion and midfoot procedures.
CEO Mr. John T. Treace · 450 employees · United States · https://www.treace.com
